Bacterial isolates
Inclusion criteria for bacterial isolates, and transportation, storage, re-identification and the microbroth dilution susceptibility testing methods have been described in detail previously. 7, 8 In brief, centres were requested to collect up to 400 isolates from patients with community-acquired lower respiratory tract infection. Centres were instructed to avoid sending duplicate isolates from the same patient. Originally, the project accepted isolates of S. pneumoniae, H. influenzae, Haemophilus parainfluenzae, M. catarrhalis, Staphylococcus aureus and Klebsiella pneumoniae. However, by 1995 the consensus view of the project group was that H. parainfluenzae and K. pneumoniae should no longer be included, in view of the low numbers submitted for testing and their lesser importance in communityacquired respiratory tract infections. Isolates of S. aureus were collected up to and including 1997, but were submitted by only a few centres. Analysis of the MIC data produced has not, therefore, been undertaken for this species and further isolates will not be collected.
Antimicrobial susceptibility testing
MICs were determined at the central laboratory in London, using a broth microdilution method (Mueller-Hinton) with an inoculum of c. 10 4 cfu in 50 L of medium. 7, 8 Breakpoint concentrations used to interpret MIC data qualitatively were based upon those published by the National Committee for Clinical Laboratory Standards of the USA (NCCLS, 1998), 9 and are indicated in the tables and text. During the period covered by the Alexander Project, re-appraisal of the breakpoints defining susceptibility to certain antimicrobials has been undertaken by the NCCLS, and these new breakpoints will be used in this analysis. 
Results

Antimicrobial resistance in S. pneumoniae strains
A total of 2160 isolates of S. pneumoniae were submitted in 1996 and 2036 in 1997. Numbers collected by individual centres, with the percentage of penicillin-susceptible, -intermediate (MIC 0.12-1 mg/L) and -resistant (MIC 2 mg/L) isolates are presented in Table I .
Of the European centres included from the beginning of the Alexander Project, France and Spain are established as areas with high rates of S. pneumoniae penicillin resistance, with combined numbers of intermediate and resistant strains now accounting for some 50% of isolates submitted from these countries. Penicillin resistance is now reported in isolates from centres in the UK (London) and Italy (Genoa), but numbers remain low at present. Between 1992 and 1997, no penicillin-resistant strains were detected in Weingarten (Germany), but intermediate strains rose from 4% in 1996 to 14.5% in 1997. It will be interesting to 
Susceptibility of S. pneumoniae to -lactams
The comparative in vitro activities of the various -lactam antimicrobials for S. pneumoniae tested in the study are shown in Table II . No change in the overall activity of the compounds against penicillin-susceptible isolates was observed. However, a general two-fold increase in MIC 90 for all compounds except penicillin was seen, indicating a small change in distribution of MIC for the aminopenicillins and cephalosporins. For both years, as in those preceding, the most active compounds were ceftriaxone and co-amoxiclav.
The comparative susceptibilities of isolates of S. pneumoniae to -lactams, using published breakpoints (NCCLS, 1998), 9 are also shown in Table II . Again, the two most active compounds were ceftriaxone (85% in 1997) and co-amoxiclav (84.2% in 1997).
Susceptibility of S. pneumoniae to non--lactams
Overall rates of macrolide resistance for isolates of S. pneum o n i a e collected in 1996 and 1997 at 16.5 and 21.9%, respectively, now exceed those of penicillin resistance (10.4 and 14.1%, respectively), and are close to the combined rates of penicillin-resistant and penicillin-intermediate isolates (24.3% in 1997) (Table III) . Similarly high resistance rates (21.8% in 1997) were found for doxycycline (Table IV) , with high rates amongst isolates from Hong Kong, Poland, Spain, France, Italy, Belgium, Hungary and Mexico and, in 1997, Saudi Arabia, South Africa and the USA.
Chloramphenicol resistance (Table IV) was less common than penicillin, macrolide, doxycycline and co-trimoxazole resistance, with relatively high rates found in isolates from Hong Kong, Spain, France, the Slovak Republic, Poland, Italy, Mexico, the USA and Saudi Arabia.
Resistance to co-trimoxazole was widespread amongst the isolates of S. pneumoniae tested (Table IV) . Although closely associated with penicillin resistance, high rates of resistance amongst penicillin-susceptible isolates were found in Spain, Italy, Poland, Hungary, Brazil and Hong Kong.
During the period of the study, neither the MIC 50 , MIC 90 , mode MIC nor the proportion of isolates requiring 16 mg/L of ciprofloxacin or ofloxacin for inhibition have changed significantly, the vast majority of MICs following a unimodal distribution (Table V) . Of the 8081 S. pneumoniae isolates tested since the Alexander Project was initiated in 1992, 0.3% (27 isolates) required a MIC 16 mg/L of either ciprofloxacin or ofloxacin. In 1997, isolates with a MIC 16 mg/L came from France (n 1), Spain (n 1), Germany (n 1), Poland (n 1), USA (two isolates, both from New York) and Hong Kong (n 5).
Overall, the most active agents in 1996-1997 in terms of potency and percentage susceptibility against S. pneumoniae were ceftriaxone and co-amoxiclav.
Relationship between the susceptibilities of S. pneumoniae to different antimicrobials
Resistance to non--lactam compounds was associated with penicillin resistance, with the exception of the fluoroquinolones (Tables III and IV) . This association was most evident for co-trimoxazole, with more than 90% of penicillin-resistant isolates resistant to this agent. Approximately 50% of all penicillin-resistant isolates were also resistant to the macrolides, doxycycline and chloramphenicol.
Of particular interest are differences in the distribution of macrolide resistance amongst penicillin-susceptible and penicillin-resistant isolates from various locations. Isolates from France (Toulouse), Spain (Barcelona), Belgium (Leuven), Italy (Genoa) and Hong Kong exhibited high rates of macrolide resistance (Table III) . However, within these five centres it is clear that different selective pressures are operating. For example, in Barcelona the majority of macrolide-resistant isolates are also penicillin resistant, whereas in Toulouse, Belgium and Hong Kong, macrolide resistance is also emerging rapidly in penicillin-susceptible isolates. A different pattern is apparent in Genoa, Italy, where macrolide resistance in excess of 20% is seen in penicillin-susceptible isolates. This is in an area in which the combined level of intermediate and resistant isolates is low (7.3% in 1997). The development of macrolide resistance independently of penicillin resistance is also seen in isolates from some, but not all, of those centres with more modest levels of macrolide resistance, including the UK, the Republic of Ireland, Switzerland, Hungary, Poland, the Slovak Republic, the USA, Mexico and Saudi Arabia. In Germany, Austria, the Czech Republic, The Netherlands, Portugal, Brazil and South Africa, macrolide resistance occurs at a relatively low level ( 10%).
Antimicrobial resistance in H. influenzae
A total of 2820 isolates of H. influenzae were collected in 1996 and 2721 in 1997. The principal mechanism of resistance observed was the production of -lactamase, with an overall rate of 13.4% in both 1996 and 1997 (Table  VI) . Large numbers of -lactamase-producing strains were found in Hong Kong, Spain, France, Belgium, the Republic of Ireland, the USA, Mexico and Saudi Arabia. -Lactamase-negative, ampicillin-resistant strains (MIC 4 mg/L) were identified only rarely, with overall rates of 0.1% in 1996 and 0.3% in 1997. In 1996, four strains were found in Barcelona, Spain. In 1997, strains were isolated in Dublin, Republic of Ireland (n 3), Portugal (n 1) and the Slovak Republic (n 2).
Antimicrobial susceptibility of H. influenzae
Of the -lactam antimicrobials tested, co-amoxiclav, cefixime and ceftriaxone were the most active against H. influenzae, followed by cefuroxime and cefaclor (Table  VII) .
Rates of chloramphenicol resistance were low (1.9% in 1997); higher rates were seen in Brazil, Hong Kong, Saudi Arabia, Spain, the Republic of Ireland, South Africa, Belgium and France (Table VI) . Analysis of chloramphenicol-resistant strains from the 6 years of collection indicates clearly an association with -lactamase production (Table VIII) .
Rates of doxycycline resistance of 1-2% were seen in centres in The Netherlands, Hungary, Poland and Saudi Arabia. Relatively higher rates were seen in São Paulo, Brazil and Hong Kong. Resistance levels of less than 1% were found in all other centres (Table VI) .
Co-trimoxazole resistance was high in Barcelona, Spain, São Paulo, Brazil and Riyadh, Saudi Arabia and less than 10% in all other centres except those in Italy, Austria, the Slovak Republic, Hungary, Poland, USA, Mexico, South Africa and Hong Kong (Table VI) .
Fluoroquinolone resistance was detected in four isolates in 1996 (one each in London, Toulouse, Barcelona and New York) and in one isolate from Portugal in 1997, making a total of 13 fluoroquinolone-resistant strains out of 11,539 isolates of H. influenzae examined in the Alexander Project since 1992-an overall rate of 0.1%.
The susceptibility of H. influenzae isolates to the macrolides followed a unimodal distribution in the rank order, azithromycin (mode MIC 0 (Table IX) . Only eight of 11,539 isolates required 8 mg/L azithromycin for inhibition.
Antimicrobial susceptibility of M. catarrhalis
-Lactamase production was the only resistance mechanism of importance identified in the isolates of M. catarrhalis tested. Overall, 90.4% of the 655 isolates collected in 1996 and 91.6% of 685 in 1997, produced -lactamase (Table X) .
Co-amoxiclav and cefixime were the most active of the -lactam compounds tested (MIC 90 0.25 mg/L) followed by ceftriaxone (MIC 90 1 mg/L) and cefaclor (MIC 90 2 mg/L) ( Table X) . Using the NCCLS breakpoints for H. influenzae, 9 more than 99% of a total of 2998 isolates of M. catarrhalis tested since the project was established in 1992 would be considered susceptible to these compounds.
The rank order of activity of the three macrolides tested was azithromycin (MIC 90 0.03 mg/L) clarithromycin (MIC 90 0.12 mg/L) erythromycin (MIC 90 0.25 mg/L). No macrolide resistance was detected in isolates from 1996 and 1997; all were inhibited by 1 mg/L erythromycin, 0.5 mg/L clarithromycin and 0.12 mg/L azithromycin (Table X) .
All isolates of M. catarrhalis tested were susceptible to the fluoroquinolones and chloramphenicol, at least 99.7% to doxycycline and 97% to co-trimoxazole.
Discussion
The data presented here add to those previously reported. 7, 8, 12, 13 However, a number of specific points need to be discussed in respect of this data group.
S. pneumoniae resistance
New centres in western Europe and eastern Europe showed high rates of S. pneumoniae resistance, though further data are required in order to elucidate trends. In particular, data from Dublin, Republic of Ireland, indicate that the high rates of resistance observed in Belfast, UK (1992) (1993) (1994) (1995) , are also present in other areas of Ireland, compared with relatively low rates on the UK mainland.
Others have seen a similar pattern.
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In the USA centres, the rate of combined (intermediate and resistant) penicillin resistance has increased from 5.6% in 1992 to 18.6% in 1997 . Although the total number tested in each year has been small, this trend has also been observed in a larger study, where rates of up to 52.9% (overall 23.6%) have been reported. 15 Expansion of the Alexander Project has highlighted Hong Kong (with a rate of penicillin resistance of at least 50%) and South-East Asia as areas in which antimicrobial resistance is a major concern. 16 Fluoroquinolone-resistant pneumococci are still found only rarely, and rates have not increased during the study period (1992) (1993) (1994) (1995) (1996) (1997) . More fluoroquinolone compounds are to be included from 1998 onwards, in order to observe any effects of the introduction of new agents of this class for the treatment of respiratory tract infections.
H. influenzae resistance
Results from the Alexander Project continue to demonstrate considerable variability in the prevalence oflactamase production amongst isolates of H. influenzae worldwide. The rising trend in the USA slowed in 1997. However, Jacobs et al. 17 reported 41.6% of 1676 isolates of H. influenzae from the USA in 1997 to be -lactamase producers. The low levels observed in this study may reflect Throughout the duration of the Alexander Project, the susceptibility of H. influenzae to the three macrolides tested has not changed and the use of arbitrary breakpoints seems inappropriate. As indicated by others, considerably more pharmacodynamic and clinical trial data are necessary if useful breakpoints are to be established for those compounds. 17 Only a small number of isolates (eight of 11,539) were detected for which the MIC of azithromycin was 1 mg/L. Further work is necessary to determine the mechanism(s) of resistance of these isolates.
M. catarrhalis resistance
Although strains of M. catarrhalis resistant to other classes of antimicrobials have been reported, 18, 19 results from the Alexander Project demonstrate clearly that the great majority of clinical isolates remain susceptible to coamoxiclav, macrolides, doxycycline, chloramphenicol, the fluoroquinolones and co-trimoxazole, confirming the unique importance of -lactamase production as an antimicrobial resistance mechanism in this species. A large multi-centre USA study also found -lactamase production to be the most important mechanism of resistance in this organism. 20 
Future developments
It is anticipated that the complete, up-to-date Alexander Project data set will be made available in an electronic format in the near future. The results from 1992-1996 are available on the Alexander Network website (http://www.Alexander-Network.com). Bacterial isolates examined during the period of the study are stored, deepfrozen, in the central laboratory, representing an important resource for retrospective analysis.
The Alexander Project continues into 1998 and beyond. Additional testing centres have been established to enable processing of a greatly increased number of isolates from a wider geographical spread of collecting sites, underlining the global dimension of the study. The data collected thus far demonstrate increasing resistance rates in many countries and highlight the need for increased vigilance in monitoring and tracking changes in antimicrobial susceptibility in order to promote successful clinical therapy, maintain the utility of current agents and suggest targets for new : co-amoxiclav 4 mg/L, cefaclor 8 mg/L, cefuroxime 4 mg/L, cefixime 1 mg/L, ceftriaxone 3 mg/L, doxycycline 2 mg/L, chloramphenicol 2 mg/L, ciprofloxacin 1 mg/L, ofloxacin 2 mg/L, co-trimoxazole 0.5/9.5 mg/L.
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